Skip Navigation

Annals of Oncology 2007 18(Supplement 6):vi16-vi21; doi:10.1093/annonc/mdm218
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Cartenì, G
Right arrow Articles by Battista, C
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cartenì, G
Right arrow Articles by Battista, C
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

monoclonal antibodies anti-EGFR and anti-VEGF

Panitumumab a novel drug in cancer treatment

G Cartenì1, R Fiorentino1, L Vecchione2, B Chiurazzi1 and C Battista1,*

1 Oncology Division Azienda Ospedaliera di Rilievo Nazionale Cardarelli, Naples
2 Department of Clinical and Experimental Medicine and Surgery "F.Magrassi and A.Lanzara", Second University of Naples, Medical Oncology, School of Medicine, Naples, Italy

* Correspondence to: C. Battista, Oncology Division A.O.R.N Cardarelli, via A. Cardarelli, 9–80131 Naples, Italy. Tel: +39-081-747-22-25; Fax: +39-081-747-22-21; E-mail: camibat{at}tin.it

The epidermal growth factor receptor (EGFR) is a member of the erbB family overexpressed in most of the solid tumors. In cancer cells, the overexpression of EGFR correlates with the development and the progression of tumor. Panitumumab is a fully human monoclonal antibody that blocks the extracellular domain of the EGFR and has not been associated with the formation of any antibodies directed against it. This review summarizes on the preclinical and clinical development of panitumumab in human solid tumors. As bevacizumab and cetuximab have been approved for colorectal cancer because of their improvements in progression-free survival and overall survival when associated with chemotherapy, panitumumab represents an interesting molecule which needs more phase III studies to validate its efficacy.

Key words: colorectal cancer, fully human monoclonal antibody, panitumumab, target therapy


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Journal of Pharmacy PracticeHome page
M. B. Toma and P. J. Medina
Update on Targeted Therapy--Focus on Monoclonal Antibodies
Journal of Pharmacy Practice, February 1, 2008; 21(1): 4 - 16.
[Abstract] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.